Back

@gpollara @jopo_dr very interesting. Thought it might not be a one-size-fits-all.
The big question would who will benefit the most ?
That’s where the money is. Identifying the patient with the “good” patho-phenotype who would benefit from it.

@matdesgro @jopo_dr yes, i think that's likely to be true as well - personalised approach to tackle heterogeneity.

Sepsis not my thing, but likely to be applicable in many diseases.

@gpollara @matdesgro I would like to see patients stratified by IL-6 etc at least in once study. Sub group analysis of CORTICUS etc shows there is a hyper inflammatory and a immune paresis phenotype in sepsis - can enrich which might benefit from different therapies but need rapid bedside testing because so fast and florid

@jopo_dr @matdesgro yes totally agree - has to be bedside assessment of immune / cytokine activity to inform choice of host-directed therapy.

@gpollara @jopo_dr I agree too. There’s pretty much a group of patient that would benefit from it.

You’re right! how can clinician could have timely access to that data for a patient. That’s what’s gonna make it practical & useful for most clinicians

@jopo_dr @gpollara agreed. But looking at sepsis research at the moment, I have the feeling Pharma isn’t interested anymore as lasts years haven’t been good for them. They think they haven’t that much money to gain anymore. They wouldn’t have return on their investment. Protein C saga? scalded cat fears cold water